Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

NCT05225259 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Thyroid Neoplasms

Interventions

DRUG: LOXO-260

Sponsor

Eli Lilly and Company

Collaborators

[object Object]